Should I Buy ZKIN? ZKIN 2026 Analysis

Should You Buy ZK International Group Co Ltd (ZKIN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.670

1 Day change

-4.57%

52 Week Range

4.470

Analysis Updated At

2026/01/26

ZKIN is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The lack of significant positive catalysts, absence of trading signals, and neutral sentiment from hedge funds and insiders suggest limited immediate growth potential. Additionally, the technical indicators and options data do not strongly support a compelling entry point at this time.

Technical Analysis

The MACD histogram is positive and expanding (0.0636), indicating a bullish trend. RSI is at 69.076, which is neutral but approaching overbought levels. Moving averages are converging, suggesting indecision in price action. The pre-market price is $2.06, with resistance at $2.032 and $2.211, and support at $1.453 and $1.274.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

NULL identified. No recent news or significant insider/hedge fund activity. MACD indicates a slight bullish trend.

Neutral/Negative Catalysts

No recent news or significant trading trends. Stock trend analysis suggests a potential short-term decline (-0.59% in the next day, -2.8% in the next week). High implied volatility (543.38) indicates uncertainty.

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst ratings or price target changes available for ZKIN.

Analyst Rating

Wall Street analysts forecast ZKIN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZKIN is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy